Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: current (495), contemporary (32), relevant (975)

Sexual function after radical cystectomy - Information for women - patient information

Description: This factsheet explains how a radical cystectomy can affect sexual function and ways to help manage these changes.
Url: /Media/UHS-website-2019/Patientinformation/Surgery/Sexual-function-after-radical-cystectomy-Information-for-women-3743-PIL.pdf

Dacomitinib

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DACOMITINIB Regimen • NSCLC - Dacomitinib Indication Dacomitinib for untreated EGFR-posit
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Dacomitinib.pdf

Alternatives to HRT for symptoms of the menopause - patient information

Description: This factsheet contains some non-hormonal alternatives and lifestyle changes you can try to help manage your menopausal symptoms.
Url: /Media/UHS-website-2019/Patientinformation/Womenshealth/Alternatives-to-HRT-for-symptoms-of-the-menopause-3081-PIL.pdf

Cetuximab-Encorafenib

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-ENCORAFENIB Regimen • Colorectal Cancer – Cetuximab-Encorafenib In
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Encorafenib.pdf

Apalutamide v1

Description: Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

Ipilimumab Ver 1

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisa
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Pembrolizumab2mg/kg

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option for treating locally ad
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Pembrolizumab_400mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The treatment of untreated PD-L1 positive metastatic non-small-
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description: Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untreated PD-L1 positive metastatic non-small-
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

1 to 10 of 58

Previous 1 2 3 4 5 … Next